2024-516806-49-00招募中2 期
IMPD-Q-only application
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 39
- 试验地点
- 5
- 主要终点
- IMPD-Q-only application
研究概览
简要总结
IMPD-Q-only application
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •IMPD-Q-only application
排除标准
- •IMPD-Q-only application
结局指标
主要结局
IMPD-Q-only application
IMPD-Q-only application
次要结局
未报告次要终点
研究者
AZ Clinical Study Info Center
Scientific
AstraZeneca AB
研究点 (5)
Loading locations...
相似试验
进行中（未招募）
4 期
TERESA study (TERESA study)JPRN-jRCTs071230026Okamoto Isamu105
进行中（未招募）
1 期
REVErsing airway Remodelling with Tezepelumab (REVERT)exacerbating asthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2022-002891-35-FRniversity Hospital of Montpellier90
已完成
不适用
Comparative Efficacy and Safety of Tezepelumab and Dupilumab in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-AnalysisBronchial asthmaJPRN-UMIN000044672Showa University School of Medicine5,524
进行中（未招募）
3 期
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.Severe AsthmaNCT06473779AstraZeneca326
招募中
3 期
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING).Eosinophilic EsophagitisJPRN-jRCT2021230017Ageishi Yuji360